Navigation Links
Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
Date:11/12/2007

SAN DIEGO, Nov. 12 /PRNewswire/ -- Verus Pharmaceuticals, Inc., a pediatric-oriented specialty pharmaceutical company, announced today that Robert W. Keith has been promoted to President & Chief Executive Officer. Prior to the promotion, Mr. Keith served as President & Chief Operating Officer. As a result of the promotion, Cam L. Garner now will serve exclusively as Executive Chairman.

"We are excited to announce this well-deserved promotion," said Cam L. Garner. "As a co-founder of Verus, Bob has played a critical role in the development and evolution of the company from day one to the present, including our recently announced transaction with AstraZeneca."

"I am honored to take the reins from Cam at this point in time and lead the company forward as we continue to build value in our commercial franchise and accelerate our efforts on our emerging development programs," said Robert W. Keith.

The composition of the Board of Directors will not change with the promotion of Mr. Keith. In addition to Mr. Garner and Mr. Keith, the other current members include James C. Blair, Alex E. Barkas, Jean-Pierre Naegeli, Nicholas J. Simon, David F. Hale, and Erle T. Mast.

About Verus

Verus Pharmaceuticals is dedicated to improving the lives of children and those who care for them. Verus is building a portfolio of products for the unmet medical needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus is differentiated by its pediatric orientation and its strong financial position and experienced management team, which allows the company to capitalize on an extensive network to build its product portfolio and pursue complementary transactions. The company's rigorous, disciplined approach to strategic decision-making and core competencies in development and commercialization is expected to provide significant value to its partners. More information
'/>"/>

SOURCE Verus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... to 70% of Parkinson,s disease (PD) patients experience ... life. Some patients have disturbed sleep/wake patterns such ... other patients may be subject to sudden and ... patients may exhibit REM-sleep behavior disorder (RBD), characterized ... before motor symptoms appear. A review in the ...
(Date:7/10/2014)... Rutgers University-Newark says the human brain operates much the ... that could provide a better understanding of schizophrenia, bipolar ... an estimated 13.6 million Americans. , In newly published ... an assistant professor at the Center for Molecular and ... a person at rest is basically the same as ...
(Date:7/10/2014)... Manchester scientists have shown that a new drug could prove ... aggressive form of lung cancer. , Scientists from the Cancer ... and part of the Manchester Cancer Research Centre, teamed up ... in 2010, to test a drug known as AZD3965 ... published in the journal Clinical Cancer Research , also ...
(Date:7/9/2014)... first time, researchers have access to detailed information about ... care. A new study, called Our Health Counts, uses ... faced by urban Aboriginal people in Canada according ... findings, published today in BMJ Open , illustrate ... general population. , Researchers interviewed 554 First Nations adults ...
(Date:7/9/2014)... hidden ways that cells are regulated, scientists at Rockefeller ... cells more likely to metastasize. , What,s more, the ... blocking two other proteins that are normally linked to ... could have unexpected ties. , The study, which ... , points to the possibility of new cancer therapies ...
Breaking Medicine News(10 mins):Health News:Sleep disturbances, common in Parkinson's disease, can be early indicator of disease onset 2Health News:Working to loosen the grip of severe mental illness 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3
... the 150 million customer mark, an intense debate continues ... once led by nonprofits. "Microfinance Meets the Market," just ... advances the debate, presenting new research from Jonathan Morduch ... University,s Wagner Graduate School of Public Service, and Robert ...
... better balance in a slippery situation , , FRIDAY, Feb. ... where the footing is unstable helped train them to ... says a University of Illinois at Chicago study. ... develops fall prevention strategies that can be used in ...
... Ill., Feb. 20 Abbott ( NYSE: ABT ) ... from the European Commission for its acquisition of Advanced ... the outstanding shares of common stock of AMO. ... the condition to the tender offer related to European ...
... CHADDS FORD, Pa. and DANBURY, Conn., Feb. 20 ... Pharmaceuticals (Nasdaq: PPCO ) announced today that ... LLC regarding the production and sale of generic formulations ... Endo and Penwest have agreed to dismiss their ...
... FOR RELEASE UNTIL 4:00 P.M., ET, FRIDAY, FEBRUARY 20, ... Bride, (651) 695-2795, jmacbride@aan.com , Young Smokers Increase ... start smoking before age 17 may increase their risk ... released today that will be presented at the American ...
... Treatment targeting damaged brain areas did not bring significant ... (HealthDay News) -- An experimental laser treatment of ... stroke patients, researchers report. , The trial was the ... stroke. , In the trial, the researchers at the ...
Cached Medicine News:Health News:Research reveals best paths for success as microfinance sector grows 2Health News:Adapting Gait May Help Elderly Avoid Falls 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 2Health News:Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 2Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 3Health News:Endo and Penwest Announce Settlement of Opana(R) ER Litigation 4Health News:Laser Therapy Disappoints in Stroke Trial 2
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ... agreement with Hitachi Koki of Japan ... North America . NuAire will utilize its network ... and Canada to offer assistance in application ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014   Evidera ... healthcare industry, announced that the Center for Drug Evaluation ... released its first draft qualification guidance document for a ... of Exacerbations of Chronic Pulmonary Disease Tool [EXACT] for ...
Breaking Medicine Technology:NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Inquire...
Guaranteed leak-proof , Teflon coating is impervious to corrosive materials , Shock-resistant , NBS tolerances of accuracy , Thermometers are 225 mm long with an immersion length of 35 mm ...
... efficient refrigerator on the market today. The ... unit. The contoured drain channels away moisture ... walls are coated with a tough, baked-on ... door is reversible. The interior of the ...
Medicine Products: